First-Line immune checkpoint inhibition for advanced non-small-cell lung cancer: state of the art and future directions
Affiliation
Department of Medical Oncology, Spital STS AG, Thun, Switzerland.Issue Date
2020
Metadata
Show full item recordAbstract
The advent of PD-(L)1 and CTLA-4 immune check point inhibitors (CPIs) has dramatically changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC). For up to a quarter of patients with advanced NSCLC, CPIs have the potential to induce durable responses with long-term survival outcomes. Since the approval of first-line pembrolizumab for patients whose tumors express a PD-L1 ? 50%, several pivotal first-line CPI-based phase 3 studies have been conducted investigating combination treatments combining CPIs with chemotherapy (ChT) or combining different CPIs with or without ChT. As a result, there has been an increase in front-line treatment options for advanced NSCLC, and treatment algorithms are changing very quickly. In fit patients with advanced NSCLC, combination treatments including CPI and ChT are considered the new standard of care with improved clinical outcomes. CPI combination treatments are well tolerated and quality of life also seems to be better when CPIs are implemented in the first-line setting. The aim of this review is to provide a summary of the recently published first-line phase 3 studies investigating CPIs as monotherapy or in combination with other CPIs or ChT in advanced NSCLC, and to suggest possible treatment algorithms.Citation
Ackermann CJ, Adderley H, Ortega-Franco A, Khan A, Reck M, Califano R. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. Drugs. 2020;80(17):1783-97.Journal
DrugsDOI
10.1007/s40265-020-01409-6PubMed ID
32986224Additional Links
https://dx.doi.org/10.1007/s40265-020-01409-6Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s40265-020-01409-6
Scopus Count
Collections
Related articles
- Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
- Authors: Xu Q, Zhang X, Huang M, Dai X, Gao J, Li S, Sheng L, Huang K, Wang J, Liu L
- Issue date: 2021
- Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
- Authors: Teng MM, Chen SY, Yang B, Wang Y, Han RY, An MN, Dong YL, You HS
- Issue date: 2021 Sep
- Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
- Authors: Hayashi H, Nakagawa K
- Issue date: 2020 May
- Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
- Authors: Chen XJ, Ren A, Zheng L, Zheng ED, Jiang T
- Issue date: 2021
- Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
- Authors: Ellis PM, Vella ET, Ung YC
- Issue date: 2017 Sep